Omada Health releases new data on its GLP-1 companion program

Omada Health (OMDA) released new data demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss. Omada’s analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings. Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks, 42% to 80%, and 24 weeks, 33% to 74%, after starting GLP-1s. In contrast, members included in this analysis of Omada’s Enhanced GLP-1 Care Track demonstrated higher persistence rates-94% through 12 weeks and 84% through 24 weeks